Fremanezumab

(Ajovy)

Fremanezumab

Drug updated on 6/23/2023

Dosage FormInjection (subcutaneous; 225 mg/1.5 mL)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the preventive treatment of migraine in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Ajovy (Fremanezumab-vfrm) Prescribing Information.2022Teva Pharmaceuticals USA, North Wales, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Fremanezumab for preventing migraine. 2022NICE
Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene related peptide and its receptor for the prevention of chronic migraine: a network meta analysis of randomized controlled trials.2022Neurotherapeutics
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.2022European Journal of Medical Research
Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials. 2021Naunyn-Schmiedeberg's Archives of Pharmacology
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials. 2021Journal of the Neurological Sciences
Calcitonin Gene-related peptide monoclonal antibodies versus botulinum neurotoxin A in the preventive treatment of chronic migraine: an adjusted indirect treatment comparison meta-analysis. 2021Frontiers in Pharmacology
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Calcitonin gene–related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: evidence from indirect treatment comparison. 2021Frontiers in Pharmacology
Clinical review report: fremanezumab (Ajovy). 2021CADTH
Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis.2021CNS Drugs
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Quality of life related to functional disability in migraine patients: a systematic review and network meta-analysis.2021The Clinical Journal of Pain
Safety and efficacy of fremanezumab for the prevention of migraine: a meta-analysis from randomized controlled trials. 2020Frontiers in Neurology
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. 2020BMC Neurology
Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta‑analysis of randomized clinical trials. 2020Scientific Reports
Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison. 2020Farmacia Hospitalaria
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. 2019Cephalalgia
Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. 2018ICER

Clinical Practice Guidelines